Carbapenem-Sparing Strategies for ESBL Producers: When and How
Extended spectrum β-lactamase (ESBL)-producing bacteria are prevalent worldwide and correlated with hospital infections, but they have been evolving as an increasing cause of community acquired infections. The spread of ESBL constitutes a major threat for public health, and infections with...
Main Authors: | Ilias Karaiskos, Helen Giamarellou |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Antibiotics |
Subjects: | |
Online Access: | https://www.mdpi.com/2079-6382/9/2/61 |
Similar Items
-
Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
by: Allison M. Gibble, et al.
Published: (2015-12-01) -
Antimicrobial susceptibility changes of Escherichia coli and Klebsiella pneumoniae intra-abdominal infection isolate-derived pathogens from Chinese intra-abdominal infections from 2011 to 2015
by: Zhang H, et al.
Published: (2019-08-01) -
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli
by: Yu Bin Seo, et al.
Published: (2017-06-01) -
Fosfomycin Resistance in <i>Escherichia coli</i> Isolates from South Korea and <i>in vitro</i> Activity of Fosfomycin Alone and in Combination with Other Antibiotics
by: Hyeri Seok, et al.
Published: (2020-03-01) -
A meta-analysis of piperacillin/tazobactam versus cefepime treatment in cancer patients with febrile neutropenia
by: Zhang Weidong, et al.
Published: (2016-12-01)